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Background. The prevalence of HIV is the highest in sub-Saharan Africa; South Africa (SA) is one of the most affected countries with the 
highest number of adults living with HIV infection in the world. Besides the traditional risk factors for cardiovascular disease (CVD) in 
the general population, in people living with HIV there are specific factors – chronic inflammation, metabolic changes associated with the 
infection, therapy, and lipodystrophy – that potentially increase the risk for developing CVD. 
Objective. This study proposes a screening discriminant model to identify the most important risk factors for the development of CVD in 
a cohort of 140 HIV-infected black Africans from the North West Province, SA. 
Methods. Anthropometric measures, systolic blood pressure, diastolic blood pressure and the carotid-dorsalis pedis pulse wave velocity 
were determined. Blood was analysed to determine the levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol, triglycerides (TGs) and glucose. Partial least squares discriminant analysis was performed as a supervised 
pattern recognition method. Independent Student’s t-tests were further employed to compare the means of risk factors on interval scales; 
for comparison of categorical risk factors between groups, χ2 tests were used. 
Results. A TG:HDL-C ratio ≥1.49, TC:HDL-C ratio ≥5.4 and an HDL-C level ≤0.76 mmol/l indicated CVD risk in this cohort of patients 
living with HIV. 
Conclusion. The results have important health implications for black Africans living with HIV as these lipid levels may be a useful indicator 
of the risk for CVD. 
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HIV prevalence is highest in sub-Saharan Africa, 
with South Africa (SA) being one of the most affected 
countries with the highest number of adults living with 
HIV in the world.[1] The use of antiretroviral therapy 
(ART) has improved the quality and life expectancy in 
the HIV-infected population worldwide.[2] The HIV-infected population 
in SA gained free access to ART through the antiretroviral (ARV) roll-out 
programme,[3] which has made HIV a manageable disease in SA.
However, infection with HIV and the treatment thereof may affect 
the heart and vasculature, leading to the development of cardiovascular 
disease (CVD),[4] which currently, after cancer, is the most frequent 
cause of death among HIV-infected individuals.[2] In SA, CVDs 
such as hypertension, atherosclerotic disease and heart failure are 
increasing among the black African population,[5,6] which could be 
exacerbated by the high number of people living with HIV in SA. 
Furthermore, the HIV-infected population is ageing and, since age is 
a major non-modifiable risk factor for CVD, the risk for CVD may 
be expected to increase progressively in this population. [2] In relation 
to CVD, HIV infection is associated with an increase in insulin 
resistance, dyslipidaemia,[7] lipodystrophy,[8,9] endothelial dysfunction,[10] 
accelerated atherosclerosis[11] and coagulation disorders. [12] Lipid 
abnormalities, characterised by low high-density lipoprotein cholesterol 
(HDL-C) and high triglyceride (TG) levels form a large part of the risk 
for CVD in the HIV-infected population, and may be related to the 
viral infection, ART or both.[4] Even though black Africans normally 
exhibit lower fasting TG and higher HDL-C levels than whites,[13] the 
HDL-C levels of HIV-infected black South Africans were found to be 
lower than the levels normally associated with increased risk for the 
development of CVD.[14] Besides the risk factors for CVD seen in the 
general population, there are specific factors in people living with HIV 
that could increase risk, i.e. chronic inflammation, metabolic changes 
associated with the infection, its therapy and lipodystrophy.
HIV-infected people are managed in clinics through the ARV 
roll-out programme in SA. Early identification and management of 
CVD complications is essential, but also difficult as resources are not 
always readily available. The development of a non-invasive tool to 
help identify individuals who are most likely to derive clinical benefit 
from CVD risk-reduction therapy is therefore of great importance. 
This study aimed to identify the most important risk factors for the 
development of CVD in a cohort of 140 HIV-infected black Africans 
from the North West Province, SA. 
Methods 
Study design and participants
This cross-sectional sub-study is embedded in the international 
Prospective Urban and Rural Epidemiology (PURE) study, which was 
designed to address questions regarding the cause and development of 
cardiovascular risk factors and disease.[15] In the present sub-study we 
included 154 HIV-uninfected and 140 HIV-infected persons known 
to be infected for at least three years. Data collection took place in 
2008 and the 140 HIV-infected participants were used in a hierarchical 
cluster analysis[16] to separate participants with and without risk for the 
development of CVD. HIV-infected participants were stratified into 
risk and no risk groups and the following variables were assessed: age; 
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body mass index (BMI); waist-to-hip ratio; systolic blood pressure 
(SBP); diastolic blood pressure (DBP); carotid-dorsalis pedis pulse 
wave velocity (cdPWV); total cholesterol (TC); HDL-C; low-density 
lipoprotein cholesterol (LDL-C); TG; TG:HDL-C ratio; TC:HDL-C 
ratio; and glucose. The group identified by the analysis as exhibiting 
CVD risk factors was cross validated for the cut-off values for CVD risk 
according to the SA guidelines.[17] All the participants in the CVD risk 
group exhibited one or more CVD risk factors. The cluster analysis was 
based on the cardiometabolic profile of the HIV-infected participants 
and was used to separate the HIV-infected participants into a group 
exhibiting risk factors for the development of CVD and a group without 
CVD risk factors.
Of the participants, 63 received ART consisting of two nucleoside 
reverse transcriptase inhibitors (stavudine and lamivudine) plus 
one non-nucleoside reverse transcriptase inhibitor (efavirenz or 
nevirapine). Twenty of the 63 participants had received ART for 
>2 years. The mean CD4+ cell count for those receiving ART was 
260 cells/μl and for those not receiving ART was 264 cells/μl. 
All participants provided signed informed consent after all 
procedures were explained in their home language. The study 
protocol complies with the Declaration of Helsinki as revised in 
2008 and was approved by the Ethics Committee of the North-West 
University, Potchefstroom, SA (code 04M10).
Experimental protocol
During data collection, the participants arrived at the research locality 
of the rural or urban areas at 08h00 each morning after a 10 - 15-min 
drive (provided by the research team) from their communities. The 
participants were introduced to the planned research and, after the 
procedures were explained, they signed informed consent forms 
and received HIV pre-counselling from trained counsellors. In the 
course of the morning, demographic and lifestyle questionnaires 
were completed with the help of specially trained field workers in 
each subject’s home language. Lifestyle data included self-reported 
current tobacco and alcohol use as well as medical history. Referrals 
to the local clinic or hospital, if necessary, and feedback on HIV status 
and cardiovascular variables were provided to participants during 
individual post-counselling.
Anthropometric measurements
Height, weight, hip and waist circumference (WC) were measured 
(Precision Health Scale, A & D Company, Japan; Invicta Stadiometer, 
IP 1465, UK; Holtain unstretchable metal tape) using standardised 
procedures.[18]
Demographic questionnaire
Demographic and lifestyle information were obtained from the 
above-mentioned questionnaire.
Cardiovascular measurements
SBP and DBP were obtained with the validated OMRON HEM-757 
apparatus (Omron Healthcare, Japan). After a 10-min rest period, 
blood pressure measurements were performed twice (5 min apart) 
on the right arm while the participant was seated upright and relaxed 
with his/her right arm supported at heart level. Appropriate sized 
cuffs were used for obese participants.
Pulse wave velocity, a measure of arterial stiffness, was measured 
on the left side of each participant in the supine position. The 
measurement was determined using non-invasively accessible 
superficial pulses with the Complior SP device (Artech-Medical, 
France) in a segment over the carotid-dorsalis pedis vessels.
Blood, serum and plasma samples
The subjects were required to fast overnight. Blood was drawn from 
the brachial vein using a sterile winged infusion set and syringes. 
Serum and plasma samples were prepared according to appropriate 
methods and stored at -80°C. In rural areas, samples were stored 
at -18°C (for no longer than five days) until transported to the 
laboratory facility and then stored at -80°C until analysis.
Biochemical analysis
Quantitative determinations of the TC, HDL-C, TG and glucose were 
performed with the Beckman Coulter DxC 800 Synchron Clinical 
System (Beckman Coulter Inc., USA). LDL-C was calculated by using 
the Friedewald formula.[19] HIV status was determined with the First 
Response rapid HIV card test (PMC Medical, India) using whole 
blood. If tested positive, the test was repeated with the Sensa card test 
(Seyama Solutions, SA).
Statistical analysis
Statistical analysis was performed using Statistica (version 10.0) and 
R (version 2.13). Independent Student’s t-tests were used to compare 
means of risk factors on interval scales; for comparison of categorical 
risk factors between groups, χ2 tests were used. 
Multivariate analysis was performed in the form of pattern 
recognition methods. Pattern recognition methods are commonly 
divided into supervised and unsupervised methods, where supervised 
methods make use of the grouping of information in the data. Prior to 
multivariate analysis, the input data were scaled using the transformation 
Y = log[X/X], where X is the arithmetic mean. This transformation was 
applied to make the scales of the CVD risk factors more comparable, so 
that the factors with larger scales would not dominate in the multivariate 
analysis. Hierarchical cluster analysis using the method of Ward[16] with 
an euclidean distance measure was then performed as an unsupervised 
pattern recognition method to create two clusters of cases with similar 
multivariate profiles concerning the CVD risk factors measured. These 
clusters contain cases with and without CVD risk within the 140 HIV-
infected participants. Using these clusters as dependent variables and 
the risk factors as independent predictors, a partial least squares (PLS) 
discriminant analysis (DA) was performed as a supervised pattern 
recognition method. Although the PLS-DA model can be used to predict 
a person’s cluster membership given the CVD risk factors as input, our 
aim in fitting this model was to identify those risk factors that contribute 
most (in a multivariate sense) to the existence of the grouping (clusters) 
formed by the cluster analysis. 
The variable importance in the projection (VIP) from PLS-DA is a 
measure that is commonly used in this regard. Risk factors with a VIP 
value >1 were used as the criteria for variable selection.[20] To validate 
the interpretations made from the discriminant model, the following 
fit statistics are reported: percentage of variance explained for the risk 
factors (R2X), the percentage variance explained for the dependent 
variable (R2Y), the predictive R2Y values (Q2) and cross-validated 
estimates of sensitivity (percentage true positives) and specificity 
(percentage true negatives). The model dimension was selected 
using the Q2 statistics. The cross-validated estimates of sensitivity 
and specificity are calculated to confirm that the PLS-DA model did 
not overfit the data. Hence, whether the model could make accurate 
cluster predictions for cases unseen by the model was investigated. 
These estimates were calculated as follows: 
A PLS-DA model was constructed using all 140 cases. This model was 
used to determine a cut-off point for the model predicted value (used 
to make cluster predictions) by calculating the Youden index. [21] Then, 
10 000 unique stratified samples of size 39 (24 from cluster 1 and 15 from 
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cluster 2) were randomly selected and excluded 
from the data. This equated to an exclusion 
of ~30% of the data. For each of the 10  000 
samples, a PLS-DA model was constructed 
using the remaining cases, after which the 
cluster membership of the withheld cases was 
predicted. For each of the 10  000 trials, the 
sensitivity and specificity were recorded and 
finally averaged to find the cross-validation 
estimates of sensitivity and specificity. 
Receiver-operating characteristic (ROC) 
analysis was used to determine the optimum 
cut-off values (based on the Youden 
index) for risk and no risk in HIV-infected 
participants to develop CVD for each of the 
selected variables.[21]
Results
In Table 1, the characteristics of HIV-infected 
participants are compared with the uninfected 
control participants. The HIV-infected 
participants had significantly lower SBP, TC 
and HDL-C levels. However, their TC:HDL-C 
and TG:HDL-C ratios were significantly higher 
compared with the uninfected control group. 
The dendrogram of the cluster analysis 
of the 140 infected participants is shown in 
Fig. 1, from which a clear separation of the 
cases is visible. To identify the risk factors 
that contribute most to the separation, a PLS-
DA model was constructed using the clusters 
formed (Fig. 1) as dependent variables and 
the risk factors as independent variables. One 
component was extracted for the PLS-DA 
model based on the Q2 value. The summary 
fit statistics of the PLS-DA model indicated 
that the model accounted for only 23.2% 
of the total variance observed in the scaled 
risk factors; however, the variance explained 
for the dependent variable is 61.5%. The Q2 
value was 0.602, which indicated that the 
model did not overfit the data, and that good 
prediction performance could be expected 
if required. This was further confirmed by 
the cross-validation estimates of sensitivity 
and specificity, which were 94.4% and 93.3%, 
respectively. The respective standard errors 
of these estimates were 6% and 4.7%. From 
these statistics we concluded that the PLS-
DA model fits reasonably well and could be 
used to identify risk factors that separated the 
group into no- and high-CVD risk within the 
HIV-infected participants.
There was no statistically significant 
difference between the risk and no-risk 
groups concerning age, gender, BMI, ART, 
alcohol or tobacco use. The CD4+ count (291 
v. 225  cells/μl; p=0.08) also did not differ 
significantly when no-risk and risk groups 
were compared.
VIP values are presented in Table  2, 
from which TG:HDL-C ratio, HDL-C and 
Table 1. Characteristics of HIV-uninfected and -infected participants
HIV-uninfected 
(N=154)
HIV-infected 
(N=140) p-value
Demographic
Age (years), mean (±SD) 48.3 (±8.25) 47.3 (±7.01) 0.28
Gender (male), n (%) 57 (37) 45 (32) 0.38
Anthropometric, mean (±SD)
BMI (kg/m2) 23.7 (±5.91) 22.7 (±5.55) 0.15
WC (cm) 78.2 (±10.5) 76.1 (±11.7) 0.11
Waist:hip ratio 0.83 (±0.08) 0.82 (±0.09) 0.59
Cardiovascular, mean (±SD)
SBP (mmHg) 134 (±21.6) 129 (±18.9) 0.05
DBP (mmHg) 88.6 (±13.2) 86.8 (±11.6) 0.23
cdPWV (m/s) 8.81 (±1.70) 8.52 (±1.60) 0.15
Biochemical, mean (±SD)
TC (mmol/l) 4.25 (±1.18) 3.93 (±1.14) 0.02
HDL-C (mmol/l) 1.19 (±0.55) 0.92 (±0.45) <0.01
LDL-C (mmol/l) 2.54 (±0.93) 2.49 (±0.91) 0.71
TG (mmol/l) 1.13 (±0.78) 1.19 (±0.26) 0.59
TC:HDL-C ratio 4.15 (±2.68) 4.91 (±1.94) <0.01
TG:HDL-C ratio 1.17 (±1.51) 1.66 (±1.44) <0.01
Glucose (mmol/l) 4.60 (±1.03) 4.57 (±0.77) 0.78
hsCRP (mg/l), mean (95% CI) 2.62 (0.5 - 27.3) 3.05 (0.5 - 34.4) 0.34
Lifestyle, n/N (%)†
Tobacco use 68/142 (48) 37/118 (31) <0.01
Alcohol use 72/142 (51) 46/118 (39) 0.06
SD = standard deviation; BMI = body mass index; WC = waist circumference; SBP = systolic blood pressure;  
DBP = diastolic blood pressure; cdPWV = carotid-dorsalis pedis pulse wave velocity; TC = total cholesterol;  
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglyceride;  
hsCRP = high-sensitivity C-reactive protein; CI = confidence interval.
*p-values were obtained with independent Student’s t-tests or χ2 tests.
†N = total participants who indicated their alcohol/tobacco use on the questionnaire.
Fig. 1. Dendrogram of the HIV-infected participants to show the clustering of variables.
RESEARCH
198       March 2014, Vol. 104, No. 3
TC:HDL-C ratio were identified as the risk 
factors that primarily cause group separation. 
Tobacco and alcohol use were not included 
in the PLS-DA as it was obtained from a 
self-reported questionnaire. High-sensitivity 
C-reactive protein (hsCRP) was included 
primarily in the PLS-DA but did not 
contribute to the cluster formation. To test the 
discriminatory ability of the three main risk 
factors identified, a PLS-DA model containing 
only HDL-C, TG:HDL-C and TC:HDL-C 
ratios (as independent variables) was fitted 
and cross-validated. The estimated sensitivity 
was 96.4% and the estimated specificity was 
92.1%. The respective standard errors of these 
estimates were 4.9% and 4.8%. This confirms 
that the three risk factors identified contained 
almost all the discriminatory information, 
since similar results were obtained when 
using all 13 variables in the PLS-DA model. 
The distributional properties and the 
relationship among these three risk factors are 
illustrated as a matrix-plot (Fig. 2). Categorised 
boxplots of each risk factor are on the diagonal 
and scatterplots with appropriate labels are in 
the off-diagonal entries. Each box’s height 
indicates the variability (difference between 
third and first quartile), while the median is 
the central line. The whiskers give the range 
of values except for the extremes displayed as 
individual points. 
From ROC analysis, optimum cut-off 
values were determined for the participants. 
The cut-off values between risk and no-risk 
for CVD in participants were: HDL-C 
0.76 mmol/l; TC:HDL-C ratio 5.40; and 
TG:HDL-C ratio 1.49.
Discussion
By making use of the PLS-DA statistical 
analysis method, we identified those CVD 
risk variables that contributed most (in a 
multivariate sense) to the existence of the 
grouping (clusters) observed in the total HIV-
infected group that consisted of ARV-treated 
and never-treated participants. The most 
important variables identified by the PLS-DA 
were TG:HDL-C, HDL-C and TC:HDL-C 
with values of VIP >1. ROC analysis indicated 
that a TG:HDL-C ratio ≥1.49, TC:HDL-C 
ratio ≥5.4 and an HDL-C level ≤0.76 mmol/l 
constituted risk values with the potential to 
contribute to the development of CVD in 
HIV-infected black Africans. 
The statistical PLS-DA method was 
employed to discriminate between HIV-
infected participants with risk and no risk in 
the same group. Wold et al.[22] reported that 
PLS regression is useful for the analysis of 
noisy, incomplete data where multicollinearity 
is present. The PLS-DA method is also 
useful when a large number of variables are 
investigated simultaneously. In addition, the 
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Fig. 2. Matrix plot of TG:HDL-C and TC:HDL-C ratios in no-risk (0 on boxplots;  on scatterplot) and risk (1 on boxplots; × on scatterplot) groups within 
the HIV-infected participants (HDL-C = high-density lipoprotein cholesterol; TG = triglyceride; TC = total cholesterol).
Table 2. VIP values of different CVD 
risk markers
Variable VIP
TG:HDL-C ratio 2.66
HDL-C (mmol/l) 1.68
TC:HDL-C ratio 1.16
TG (mmol/l) 0.98
LDL-C (mmol/l) 0.65
TC (mmol/l) 0.52
Glucose (mmol/l) 0.22
Age (years) 0.07
BMI (kg/m2) 0.06
Waist:hip ratio 0.05
cdPWV (m/s) 0.04
SBP (mmHg) 0.03
DBP (mmHg) 0.01
VIP = variable importance in the projection;  
CVD = cardiovascular disease; TG = triglyceride;  
HDL-C = high-density lipoprotein cholesterol;  
TC = total cholesterol; LDL-C = low-density lipoprotein 
cholesterol; BMI = body mass index; cdPWV = carotid-
dorsalis pedis pulse wave velocity; SBP = systolic blood 
pressure; DBP = diastolic blood pressure.
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PLS/VIP method is used to assist in the identification of relevant 
predictors (Table 2), while Chong and Jun[20] found that this outperforms 
other variable selection methods. 
HIV-related CVD is under-recognised and the clinical assessment 
thereof is a critical challenge for practitioners, especially in SA. 
Bearing in mind the enormous task facing the practitioners managing 
the ARV roll-out programme and the high number of people in 
SA living with HIV, the results of this study should simplify the 
identification of those individuals who exhibit a CVD risk. The 
discriminant model showed that the determination of HDL-C levels, 
and TG:HDL-C and TC:HDL-C ratios could be of clinical benefit for 
the identification of individuals at risk. It is well known that people 
living with HIV exhibit dyslipidaemia characterised by low HDL-C 
and high TG levels.[3] The latter was reported in newly identified HIV-
infected South Africans,[14] although black Africans normally exhibit 
lower fasting TG and higher HDL-C levels than whites.[13] The HDL-C 
levels seen in the total HIV-infected group in this study (0.92 mmol/l) 
were below the level (1.28 mmol/l) generally regarded as an increased 
risk of developing CVD.[23]
The cut-off values of TG:HDL-C (1.49) and HDL-C levels 
(0.76  mmol/l) seen in our study indicated that risk is lower than 
that described in the literature.[24,25] However, modified CVD risk 
equations and models such as the Framingham Risk Score have not 
been validated for use in black Africans living with HIV. Thus, in 
light of the ethnic differences in TG and HDL-C levels,[13,26] and the 
findings of this study, different cut-off values may be needed to define 
the dyslipidaemia in HIV-infected black Africans that indicates 
risk of developing CVD. However, to evaluate individual risk the 
composite risk factor profile of traditional risk factors such as gender, 
lifestyle (smoking and alcohol abuse) and family history of CVD 
must be considered.
The strength of this study is that it contributes to CVD risk data 
in HIV-infected black South Africans, which are sparse. It would 
benefit practitioners, and be clinically advantageous to use metabolic 
variables such as TG:HDL-C and TC:HDL-C ratios as well as HDL-C 
levels, to discriminate between those individuals with risk, and those 
without risk, for the development of CVD.
Study limitations
Although there were no gender or treatment differences between the 
risk and no-risk groups, a limitation of the study is that this model did 
not discriminate between gender and those who were treated and those 
who did not receive treatment. It is difficult to differentiate between 
risk associated with HIV and that associated with ART.[4] As previously 
reported, not all HIV-infected individuals eligible for treatment have 
enrolled in the ART programme[27] and, in fact, in 2009, the treatment 
coverage in SA was <40%.[1] When the interaction between treatment 
and no treatment was determined statistically in the risk groups, 
interaction was seen only in the TC:HDL-C ratio. ART (including 
nevirapine and efavirenz) was associated with the normalisation of 
HDL-C levels and an increase in TC levels.[28] 
Conclusion
Our study involved a cohort of people living with HIV in the North West 
Province, SA. Future research in larger prospective studies is warranted 
to assess the predictive power of lipid ratios and HDL-C levels for CVD 
development in people living with HIV in sub-Saharan Africa. Despite 
the limitations and the relatively small size of this study, we propose 
that by employing lipid ratios and HDL-C levels for screening, early 
identification of South Africans living with HIV and at risk for CVD 
may be achieved. A TG:HDL-C ratio ≥1.49, TC:HDL-C ratio ≥5.4 and 
an HDL-C level ≤0.76 mmol/l were indicative of CVD risk. 
These results have important health implications for black Africans 
living with HIV, as these lipid levels may be useful indicators of CVD 
risk in clinical settings. 
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